Suppr超能文献

病因是预测儿科患者室性心律失常导管消融后复发的一个因素。

Etiology is a predictor of recurrence after catheter ablation of ventricular arrhythmias in pediatric patients.

机构信息

Arrhythmia Unit and Electrophisiology Laboratories, San Raffaele Scientific Institute, Milano, Italy.

Cardiac Imaging Unit, San Raffaele Scientific Institute, Milano, Italy.

出版信息

J Cardiovasc Electrophysiol. 2021 May;32(5):1337-1345. doi: 10.1111/jce.14984. Epub 2021 Mar 13.

Abstract

BACKGROUND

Ventricular arrhythmias (VAs) are rare in pediatric patients, especially in absence of structural heart disease (SHD). Few data are available regarding the invasive VAs treatment with catheter ablation (CA) in pediatric patients and predictors of outcomes have not been fully investigated.

OBJECTIVE

To describe the clinical presentation, procedural characteristics, and outcomes in pediatric patients undergoing CA for VAs.

METHODS

Eighty-one consecutive pediatric patients (58 male [72%], 15.5 ± 2.2 years) treated by CA for ventricular tachycardia (VT) or premature ventricular beats (PVBs) were retrospectively evaluated. Study endpoints were VAs recurrence and mortality for any cause.

RESULTS

Ninety-five procedures were performed in 81 patients, 52 (55%) PVBs and 43 (45%) VT ablations. During a follow-up of 35.0 months (interquartile range = 13.0-71.0), 14 patients (14.7%) had a VA recurrence: 11 (33.3%) patients treated with CA for VT and 3 (6.2%) patients treated for PVBs (p < .001). One patient (1%) died 26 months after the procedure during an electrical storm. Patients with SHD had higher VAs recurrence rate, as compared with idiopathic VAs (pairwise log-rank p < .001). Patients treated with CA for VT had higher VA recurrence rate, as compared with PVB patients (pairwise log-rank p = .002). At Cox multivariate analysis only SHD was an independent predictor of VAs recurrence (hazard ratio = 5.56, 95% confidence interval = 2.68-11.54, p < .001).

CONCLUSION

CA of VAs is effective and safe in a pediatric population. CA of idiopathic and fascicular VAs are associated with lower recurrence rate, than VAs in the setting of SHD.

摘要

背景

室性心律失常(VA)在儿科患者中较为罕见,尤其是在无结构性心脏病(SHD)的情况下。关于儿科患者经导管消融(CA)治疗VA的相关数据较少,且其预后预测因素尚未得到充分研究。

目的

描述接受 CA 治疗 VA 的儿科患者的临床表现、操作特点和结局。

方法

回顾性分析 81 例连续接受 CA 治疗室性心动过速(VT)或室性早搏(PVB)的儿科患者。研究终点为任何原因导致的 VA 复发和死亡率。

结果

在 81 例患者中进行了 95 次操作,其中 52 次(55%)为 PVB 消融,43 次(45%)为 VT 消融。在 35.0 个月(四分位距 13.0-71.0)的随访中,14 例患者(14.7%)发生 VA 复发:11 例(33.3%)患者因 VT 接受 CA 治疗,3 例(6.2%)患者因 PVB 接受 CA 治疗(p<0.001)。1 例患者(1%)在手术后 26 个月因电风暴死亡。与特发性 VA 相比,SHD 患者 VA 复发率更高(两两对数秩检验 p<0.001)。与 PVB 患者相比,因 VT 接受 CA 治疗的患者 VA 复发率更高(两两对数秩检验 p=0.002)。Cox 多因素分析显示,只有 SHD 是 VA 复发的独立预测因素(风险比=5.56,95%置信区间=2.68-11.54,p<0.001)。

结论

在儿科人群中,CA 治疗 VA 是有效且安全的。与 SHD 相关的 VA 相比,特发性和间隔部 VA 的 CA 复发率较低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验